Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
LH
Laboratory Corporati
$264.96
Chart
$247.85 (+6.90%)
$216.98 (+22.11%)
$253.03 (+4.71%)
$233.39 (+13.53%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
LH
Laboratory Corporati
Current Price
$264.96
Hold
Login to view Laboratory Corporati (LH) recommendation from the last 90 days from financial news and social media.
Chart
$247.85 (+6.90%)
$216.98 (+22.11%)
$253.03 (+4.71%)
$233.39 (+13.53%)
LH Latest Analysis
Matrix Medical Network Announces Strategic Partnership with Molecular Testing Labs to Enhance In-Home Diagnostic Offerings. Leader In Delivering Home-Based Health and Care Services Partners with Laboratory Known for Quality Reliability and Innovation NASHVILLE Tenn. July 23 2025 /PRNewswire/ -- Matrix Medical Network (Matrix) a leader in delivering high quality home-based health and care services...
Today
Engaging In Options Activity Cornelius P. McCarthy III Exercises Options Valued At $740K In Medpace Hldgs. Highlighted on July 24 it was unveiled in an SEC filing that III Director at ) executed a significant transaction involving the exercise of company stock options.United States Securities and Exchange Commission III Director at Medpace Hldgs executed a strategic derivative sale. This involved exercising stock options for 1972 shares of MEDP resulting in a transaction value of $740111.As of F
Today
Witnessing An Insider Decision Cornelius P. McCarthy III Exercises Options Valued At $1.85M At Medpace Hldgs. In a new SEC filing on July 22 it was revealed that III Board Member at ) executed a significant exercise of company stock options.United States Securities and Exchange Commission revealed that III Board Member at Medpace Hldgs exercised stock options for 4500 shares of MEDP resulting in a transaction value of $1854045.During Wednesday'.s morning session Medpace is a late-stage contr
Wed Jul 23, 2025
Epicore Biosystems Secures $1.2M AFWERX Phase II Contract to Enhance Military Hydration Readiness. Award will help accelerate deployment of Epicore'.s Connected Hydration®. platform to support Air Force operations and training (Epicore) announces it has been selected by AFWERX the innovation arm of the Department of Air Force for an SBIR Phase II in the amount of 1 wearable platform to address the personalized hydration management and recovery needs of personnel in the Department of the A
Wed Jul 23, 2025
A Glimpse of Laboratory Corps Earnings Potential. Laboratory Corp (NYSE:) is preparing to release its quarterly earnings on Thursday 2025-07-24. Here'.s a brief overview of what investors should keep in mind before the announcement.Analysts expect Laboratory Corp to report an Investors in Laboratory Corp are eagerly awaiting the company'.s announcement hoping for news of surpassing estimates and positive guidance for the next quarter.It'.s worth noting for new investors that stock pr
Wed Jul 23, 2025
Matrix Medical Network Announces Strategic Partnership with Molecular Testing Labs to Enhance In-Home Diagnostic Offerings. Leader In Delivering Home-Based Health and Care Services Partners with Laboratory Known for Quality Reliability and Innovation NASHVILLE Tenn. July 23 2025 /PRNewswire/ -- Matrix Medical Network (Matrix) a leader in delivering high quality home-based health and care services...
Wed Jul 23, 2025
BD Board Declares Dividend. ) a leading global medical technology company today announced it has declared a quarterly dividend of About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology services and solutions that help advance both clinical therapy for patients and c
Tue Jul 22, 2025
[Latest] Global Plant Tissue Culture Market Size/Share Worth USD 1205.94 Million by 2034 at a 8.67% CAGR: Custom Market Insights (Analysis Outlook Leaders Report Trends Forecast Segmentation Growth Rate Value SWOT Analysis). Plant Tissue Culture Market Size Trends and Insights By Crop Type (Banana Plants Floriculture Plants Wood Producing Plants Fruit Plants Vegetable Plants Ornamental Plants Aquatic Plants Others) By Stage (Explant preparation and Inoculation Multiplication Hardening) By Plant
Tue Jul 22, 2025
AEMD: No SAEs in Cohort 1 Post-Hemopurifier Treatment. Progressing Trial to Cohort 2. By Data Safety Monitoring Board Recommends Progressing Trial Without ModificationAethlon Medicals (NASDAQ:AEMD) current primary focus is on researching lead asset the Hemopurifier® therapeutic blood filtration system as a potential treatment in oncology. AEMD is conducting a basket oncology trial[1] to study the impact of the Hemopurifier in patients with various solid tumors who have stable or progressive dise
Thu Jul 17, 2025
Diverging Treatment Goals Emerge Between Hematologists and Nephrologists in aHUS Care According to Spherix Global Insights. EXTON PA July 17 2025 (GLOBE NEWSWIRE) -- In the latest Special Topix™.: Co-Management Approaches in aHUS (US) Spherix Global Insights explores the nuanced dynamics between hematologists and nephrologists in the management of atypical hemolytic uremic syndrome (aHUS). Based on a quantitative survey of 103 specialists conducted between May and June 2025 the research re
Thu Jul 17, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings